MMR deficiency may also be a less prevalent driver of tumorigenesis in carriers of pathogenic MSH6 or PMS2 variants as they have a much lower CRC incidence than carriers of pathogenic MLH1 or MSH2 variants [2]. The gene discussed is MLH1; the disease is mismatch repair cancer syndrome 1.